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Περίληψη  
Ειςαγωγή. Οι παράγοντεσ που διεγείρουν τθν ερυκροποίθςθ (ESP) ζχουν χρθςιμοποιθκεί για τθ 
κεραπεία τθσ αναιμίασ ςε αςκενείσ με μυελοδυςπλαςτικό ςφνδρομο (MDS) για πολλά χρόνια. Η 
παροφςα μετα-ανάλυςθ διεξιχκθ για να εκτιμθκεί θ αποτελεςματικότθτα και θ αςφάλεια δφο 
ESP πρωτεϊνϊν, τθσ εποετίνθσ και τθσ darbepoetin ςτθν αναιμία του MDS. 
Μζθοδοι. Μια ςυςτθματικι αναςκόπθςθ και μετα-ανάλυςθ διεξιχκθ, που ςυμπεριλάμβανε 
μελζτεσ ςτθν αγγλικι γλϊςςα, από το 1998 ζωσ το 2018, ςτισ οποίεσ οι αςκενείσ ζλαβαν 
κεραπεία με ESP. Οι ςυγκεντρωτικζσ εκτιμιςεισ των ποςοςτϊν τθσ απόκριςθσ ερυκροποίθςθσ 
υπολογίςτθκαν ςε κάκε ομάδα χρθςιμοποιϊντασ μεκόδουσ μετα-ανάλυςθσ ςτακερϊν 
επιδράςεων. Η πολυπαραγοντικι ανάλυςθ μετα-παλινδρόμθςθσ διεξιχκθ περαιτζρω για τον 
ζλεγχο  διαφορετικϊν χαρακτθριςτικϊν μεταξφ των δφο ομάδων. 
Αποτελζςματα. Πζντε RCTs ςυμπεριλιφκθςαν: τζςςερεισ για τθν εποετίνθ και μία για τθ 
δαρβεποετίνθ. Οι αςκενείσ με ESP ζδειξαν ςθμαντικό πλεονζκτθμα ζναντι των μαρτφρων όςον 
αφορά τισ αποκρίςεισ αιμοςφαιρίνθσ (Hb) (OR: 5.59, διάςτθμα εμπιςτοςφνθσ 95%, 2.74-11,42). Η 
απόκριςθ τθσ Hb ιταν 24% ςτθν ομάδα ESP και 5.6% ςτουσ μάρτυρεσ. Κανζνασ από τουσ 
παράγοντεσ που επθρεάηουν τθν απόκριςθ τθσ Hb (θλικία, φφλο, αρικμόσ ςυμμετεχόντων, τφποσ 
ESP και διάρκεια ESP) δεν ιταν ςθμαντικόσ. Τα ποςοςτά των ανεπικφμθτων ενεργειϊν δεν 
διζφεραν μεταξφ των ομάδων. 
Σκοπόσ. Ο ςκοπόσ ιταν να εκτιμθκεί αν αυξάνεται θ ερυκροποίθςθ ςε αςκενείσ με MDS που 
υποβλικθκαν ςε κεραπεία με ESPs με μια ςυςτθματικι αναςκόπθςθ τθσ βιβλιογραφίασ. 
Συμπεράςματα. Δθμοςιευμζνεσ μελζτεσ υποδεικνφουν ότι οι ESP είναι αποτελεςματικζσ ςτθν 
αναιμία του MDS. Η ανταπόκριςθ τθσ Hb εμφανίηεται υψθλότερθ ςτουσ αςκενείσ που ζλαβαν ESP 
και δεν αναφζρκθκαν ςθμαντικζσ ανεπικφμθτεσ ενζργειεσ. Αλλά τα δεδομζνα για τθν 
δαρβεποετίνθ είναι λίγα και δεν υπάρχουν ακόμθ πολλζσ RCTs. 
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Abstract 
Introduction. Erythropoiesis-stimulating proteins (ESPs) have been used in the treatment of 
anemia in MDS patients for many years. The present meta-analysis was conducted to assess the 
efficacy and safety of two ESPs, epoetin and darbepoetin in anemia of myelodysplastic syndrome 
(MDS).  
Methods. A systematic review, and meta-analysis was conducted covering English-language 
studies, from 1998 to 2018, in which patients treated with ESPs was performed. Pooled estimates 
of ER rates were calculated in each group using fixed-effects meta-analysis methods. Multivariate 
meta-regression analysis was further conducted to control for different characteristics between 
the two groups. 
Results. Five RCTs qualified: 4 fουr epoetin versus controls and one darbepoetin versus controls. 
ESPs patients demonstrated a significant advantage over controls in terms of hemoglobin (Hb) 
responses (odds ratio: 5.59, 95% confidence interval, 2.74–11.42). Hb response was 24% in ESPs 
group and 5.6% in controls. .None of the analyzable predictors of Hb response (age, gender, 
number of patients, ESP type, and ESP duration) was significant in meta-regression analyses. 
Selected adverse event rates did not differ between the groups. 
Purpose. The purpose was to assess erythroid response rates in MDS patients treated with ESPs by 
performing a systematic review of the literature. 
Conclusions. Published studies suggest that ESPs are efficacious in anemia of MDS. Hb response 
appears higher in ESPs patients and no significant adverse events reported. But darbepoetin data 
are sparse, and there are not as yet many RCTs. 
 
Key Words. Anemia • MDS • Meta-analysis • Epoetin • Darbepoetin 
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Introduction 
Myelodysplastic syndromes (MDS) are a heterogenous group of hematopoietic stem cell 
disorders categorized under chronic myeloid malignancies according to the World Health 
organization (WHO) 2016 classification.1 It is characterized by abnormal proliferation and 
differentiation of hematopoietic precursors resulting in ineffective hematopoiesis, refractory 
cytopenias, and a propensity to evolve into acute myeloid leukemia (AML)2. The incidence rate of 
these conditions is about 5 cases per 100.000 persons per year in the general population, but 
increases to 20 to 50 cases per 100.000 persons per year after age 60 years. This means that 
approximately 25.000 new cases are expected in Europe each year. Moreover, considering the 
progressive aging of the population in Europe, the number of MDS patients is destined to increase 
in the next decades.3 Moreover, in the U.S. although the rates are lower, the American Cancer 
Society estimates 7.000–12.000 new cases per year.4 Although MDS is increasingly well 
understood from a biological standpoint, including discovery of 40 MDS-associated recurrently 
mutated, improved pathological in sight has not yet translated into highly effective or curative 
therapies for most patients suffering from these disorders.5 
The revised Classification 2016 WHO guidelines identify 6 entities of MDS: MDS with single 
lineage dysplasia (MDS-SLD); MDS with ring sideroblasts (MDS-RS); MDS with multi lineage 
dysplasia; MDS with excess blasts (MDSEB); MDS with isolated del (5q); and MDS unclassifiable 
(MDS-U) (Table 1). The current introduces refinements in morphologic interpretation and 
cytopenia assessment and addresses the influence of rapidly accumulating genetic information in 
MDS diagnosis and classification. Cytopenia is a “sine qua non” for any MDS diagnosis and in prior 
classifications, MDS nomenclature included references to “cytopenia” or to specific types of 
cytopenia (eg, “refractory anemia”). However, the WHO classification relies mainly on the degree 
of dysplasia and blast percentages for disease classification and specific cytopenias have only 
minor impact on MDS classification. Moreover, the lineage(s) manifesting significant morphologic 
dysplasia frequently do not correlate with the specific cytopenia(s) in individual MDS cases. For 
these reasons, the terminology for adult MDS has changed to remove terms such as “refractory 
anemia” and “refractory cytopenia” and replaces them with “myelodysplastic syndrome” followed 
by the appropriate modifiers: single vs multilineage dysplasia, ring sideroblasts, excess blasts, or 
the del (5q) cytogenetic abnormality. There are no changes to childhood MDS; refractory 
cytopenia of childhood remains as a provisional entity within this category (Table 1).1,6  
A large amount of data has recently become available on recurring mutations in MDS. 
Targeted sequencing of a limited number of genes can detect mutations in 80% to 90% of MDS 
patients; the most commonly mutated genes in MDS are SF3B1, TET2, SRSF2, ASXL1, DNMT3A, 
RUNX1, U2AF1, TP53, and EZH2.7 Importantly, acquired clonal mutations identical to those seen in 
MDS can occur in the hematopoietic cells of apparently healthy older individuals without MDS, so-
called “clonal hematopoiesis of indeterminate potential” (CHIP).2 Although some patients with 
CHIP subsequently develop MDS, the natural history of this condition is not yet fully understood; 
thus, the presence of MDS-associated somatic mutations alone is not considered diagnostic of 
MDS in this classification, even in a patient with unexplained cytopenia, where these mutations 
may be commonly found.8 
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Table 1. Classification of MDS (2016) 
Myelodysplastic syndromes (MDS) 
MDS with single lineage dysplasia 
MDS with ring sideroblasts (MDS-RS) 
MDS-RS and single lineage dysplasia 
MDS-RS and multilineage dysplasia 
MDS with multilineage dysplasia 
MDS with excess blasts 
MDS with isolated del(5q) 
MDS, unclassifiable 
Provisional entity: Refractory cytopenia of childhood 
Myeloid neoplasms with germ line predisposition 
 
Patient prognosis and risk of progression to AML can be predicted by the International 
Prognostic Scoring System (IPSS) for MDS, which is based on the presence or absence of 
multilineage cytopenias, abnormal marrow cytogenetics, and increased marrow blast counts.9  
Specific MDS treatment strategies are also based on the risk stratification by the International 
Prognostic Scoring System (IPSS) are recommended in the National Comprehensive Cancer 
Network (NCCN) Guidelines.10 Treatment choices for MDS are varied and include cyclosporine, 
thalidomide and its derivatives, tumor necrosis factor inhibitors, cytarabine, and 5-
azacytidine.Treatment to improve cytopenia is recommended for patients with IPSS low or 
intermediate-1 risk. Most patients in the lower risk categories die from causes other than 
leukemia.11 In these patients, the course of disease is marked by prolonged survival with chronic 
cytopenias and infrequent evolution to AML.  For patients with intermediate-2 or high risk, the 
guidelines recommend radical treatment with a hematopoietic stem cell transplant or treatment 
to decrease the blast count to delay the progression to AML. Bone marrow transplantation is the 
best hope for cure, but this procedure is limited by donor availability and significant toxicity, 
especially in the older population, which MDS commonly afflicts. While the ultimate goal of 
treatment is to extend survival, treatment is also intended to prevent the leukemic progression 
that occurs in up to 30% of patients. As such, for a great majority of MDS patients, the goal of 
disease management is to treat the complications of cytopenia with supportive care for anemia 
and thrombocytopenia, and antimicrobial therapy for infectious complications. Furthermore, for 
this largely incurable disease, improving quality of life (QoL), while minimizing side effects of 
therapy.9 
MDS occurs primarily in the elderly population, with a median age between 60 and 75 
years. Fatigue and exertional dyspnea may develop over a prolonged period, often exceeding 6–12 
months. These symptoms may be misinterpreted as either cardiac failure or pulmonary disease, 
particularly in elderly patients. Approximately half of the individuals are asymptomatic at the time 
of initial diagnosis and are usually diagnosed after a routine blood count. Progressive 
hematopoietic failure leading to anemia, thrombocytopenia, and leukopenia, either alone or in 
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any combination is the dominant finding in MDS. Anemia is an almost universal characteristic at 
the time of initial diagnosis; more than 80% of patients present with a hemoglobin concentration 
below 10 g/dl. The reticulocyte count usually is reduced.12 Anemia is a major contributor to the 
symptomatology of MDS, because it is associated with fatigue, weakness, and shortness of breath. 
These effects of anemia may be temporarily ameliorated by RBC transfusions. Unfortunately, 
repeated transfusions of red blood cells are associated with infectious complications, iron 
overload, and more importantly, appear to be associated with decreased survival and leukemic 
evolution in patients with MDS, although that finding might be confounded with worse underlying 
health status in patients requiring transfusions. Furthermore, transfusion therapy places great 
strain on the limited donor blood supply, which faces daily challenges of collection, processing, 
and distribution.13 
Erythropoiesis stimulating proteins (ESPs) administered either alone or in combination with 
granulocyte or granulocyte–macrophage colony-stimulating factors (G-CSF or GM-CSF), have been 
tested and used in anemic MDS patients. Also, has been extensively studied as a means to improve 
erythropoiesis and reduce red blood cell transfusions in MDS patients with anemia.14The ability of 
patients with diseased bone marrow to respond to ESPs has been questioned, and concerns 
regarding safety, especially the potentiation of leukemic progression by an exogenous growth 
factor, have been raised as possible objections to using ESPs in MDS. That’s because the use of 
ESPs was in patients with MDS from heterogeneous populations, and more importantly, the 
absence of standardized response evaluation methods, led to a tremendous variability in reported 
erythroid response rates to epoetin alfa monotherapy in published literature. In the late 1990s, it 
was found that patients with low to intermediate-1 (INT-1) disease with low transfusion 
requirements and lower endogenous serum erythropoietin levels may show the best response to 
epoetin alfa and thus may be better candidates for erythropoietic therapy.15 Recently, 
darbepoetin alfa, has also been shown to be effective in the treatment of MDS-related anemia.16 
Moreover, the last years random clinical trials of ESPs, have been conducted.17,18,19,20,21 Two meta-
analyses reported a significantly higher erythroid response with ESPs, compared to a controlled 
drug (odds ratio, 5.2; 95% confidence interval, 2.5–10.8) and also was no significant difference in 
the pooled erythroid response rates between the two agents (epoetin alfa: 57.6% vs. darbepoetin 
alfa: 59.4%; p = 0.828). 22,23 Patients with MDS are known to have higher serum erythropoietin 
(EPO) levels than healthy adults. Higher serum EPO levels are inversely associated with a patient’s 
response to ESPs. Based on these study reports, the NCCN Guidelines recommend ESAs as a first-
line treatment for MDS patients with IPSS low or intermediate-1 risk, symptomatic anemia, and a 
serum EPO level of ≤500 mIU/mL.24 In 2000, the International Working Group conducted a review 
of currently used response definitions and introduced a uniform set of criteria for assessing 
response in future clinical trials in MDS. These standardized criteria were developed in an effort to 
improve communication among investigators and to allow comparability among clinical trials. The 
advent of the International Working Group criteria (IWGc), and revision in 2006, should better 
enable the comparison of erythroid response rates to erythropoietic therapy.25 
The purpose of the present meta-analysis was: to assess erythroid response rates in MDS 
patients treated with ESPs (epoetin and darbepoetin), to gain further insights into predictors of 
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response rates, and to compare the erythroid response rates observed with epoetin alfa and 
darbepoetin. 
 
Methods 
In general, the methods used for this review followed current best practices for conducting 
systematic reviews and meta-analyses of the literature.26 
Studies 
  The literature search was electronically. MEDLINE (via PubMed) was searched using the 
following search strategy: 
 1.EPO OR epoetin OR erythropoietin OR  erythropoiesis-stimulating proteins OR darbepoetin  
2. Myelodysplastic syndromes OR MDS OR myelodysplasia.  
3. #1 AND #2. 
Also the electronic databases Scopus and Cochrane were searched for relevant citations.  
In the selection of studies were limits: Publication date 1998–2018, RCTs, English, and 
human, NOT single-arm studies, case reports, letters, news, editorials, reviews, preclinical studies, 
retrospective analyses. 
There were no restrictions on sample size and duration of study. If the relevant data for the 
analysis were available from the abstract, it was acceptable.  All RCTs and abstracts that evaluated 
the effectiveness of epoetin or darbepoetin as a monotherapy for the treatment of MDS-related 
anemia were included. Studies had to report at least one of the following outcomes of interest: 
hemoglobin (Hb) change, RBC transfusions, number of patients with Hb response. Selected 
adverse events (AEs) were also sought: deaths, patients progressing to acute myelogenous 
leukemia (AML), asthenia and fatigue. 
Randomized controlled trials (RCTs) were also critically appraised at the time of data 
extraction using the CONSORT 2010 checklist (CONsolidated Standards Of Reporting Trials). Each 
accepted RCT was scored for features of randomization method used, blinding of treatments, and 
accounting for all patients entered and withdrawn. 
Data extraction 
For each eligible study, we extracted information on authors, year of publication, countries 
of recruitment, diagnostic criteria, gender, types of ESP, number of patient, concurrent treatment 
and dosing duration. 
Statistical Analyses  
Study-, patient-, and treatment-level data were summarized using basic descriptive 
statistics (simple counts and means). The number of patients randomized or enrolled was used in 
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the calculation of study and patient demographics. The main objective of the analyses was to 
quantify and compare the efficacy for managing anemia in MDS patients. Outcomes of interest 
included: Hb response, as well as major and minor response and transfusions. 27 For IWGc studies, 
erythroid response was defined as major (i.e., increase of >2 g/dL in Hb level from baseline in 
patients with a hemoglobin of ≤11g/dL or transfusion independence for transfusion-dependent 
patients) plus minor (i.e., increase of 1–2 g/dL in Hb level from baseline in patients with a 
hemoglobin of ≤11 g/dL or 50% reduction in transfusion requirements for transfusion dependent 
patients). For the non-IWGc studies, hematologic response rate definitions were variable and 
included: favorable response, complete response, and partial response. Frequency counts and 
percentages were used to summarize categorical variables while means and standard deviations 
were used for continuous variable. 
Fixed-effect model meta-analyses were used to calculate pooled ORs with 95% CI for Hb 
response. The FE does not consider the variability across studies and assumes that the studies are 
homogeneous in terms of κi. Thus, in order to use the FE model, we first tested whether a 
significant heterogeneity across studies exists. Because heterogeneity does not exist, then is 
eligible to use the FE model; otherwise the random model should be used. The RE model is a more 
conservative methodology for combining results across studies, taking into consideration both 
within-and between-study variation. The test for heterogeneity is based on the formula Q-statistic 
which is a weighted sum of squares of the deviations of individual trial treatment difference κi 
from the pooled estimate κp.  If Q is less than the 10% point of the χ2-distribution with n-1 df 
(given from the table of the χ2-distribution), there is no significant heterogeneity across studies.28  
In addition, univariate meta-regression analyses were conducted, with supplemental descriptive 
statistics, to identify study characteristics that were significant determinants of erythroid response 
rate using epoetin alfa IWGc studies. 
The results from the studies which were meta-analyzed, are expressed as odds ratios (ORs) 
with 95% confidence intervals (CIs) for active versus control treatments. An OR <1 indicates a 
lower risk for active than for control treatment, and an OR >1 indicates a greater risk for active 
than for control treatment.29  
Meta-regressions were conducted to test the impact of some covariates upon the main 
efficacy outcome. The covariates of interest had comprehensive and well-distributed results 
available across trials. These were: number of patients, gender, ESP type (epoetin or darbepoetin) 
and ESP duration (weeks). None of the covariates were significant. Other covariates were of 
interest, but insufficiently reported to use in the meta-regression analyses of predictors.  
In the extraction of safety data, a zero was extracted only when there was a statement to 
the effect that a particular event did not occur. No assumptions were made from the absence of 
data and did not included in analyses. Moreover, it was taken in account if there is publication 
bias. The simplest and most commonly used method to detect publication bias is an informal 
examination of a funnel plot. Also, a formal test for publication bias based on linear regression 
analysis is Egger’s test. If t from Egger’s test is less than the 5% point of the t-distribution with n-1 
df, there is no indication of publication bias.  All calculations were performed using SPSS software 
version 24 (SPSS, Inc., Chicago, IL) and Revman 5.3 
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Results 
Five RCTs (n= 459) were eligible for inclusion in this meta-analysis. There were published in 
1998–2018. The four of five RCTs studied response to epoetin a and one to darbepoetin. The 
darbepoetin study was the most recent (2017). One study was available only as abstract (Miller et 
all). Three studies were in counties of Europe and two were in America. . The men outnumbered 
women (60% versus 40%), and the average age was 71 years (Table 2). Study durations (available 
in all studies) were in the range of 12–52 weeks (averaging 22.5 weeks) and dose frequency 
variable among the studies. There were no darbepoetin versus epoetin studies. Extractable Hb 
response outcomes were available in all RCTs. The distribution of groups and patients by ESP type, 
dosing duration frequency, and duration is shown in Table 3.  
ESP efficacy and safety outcomes were rarely reported by baseline risk category. Two RCTs 
studied the response in the 3 groups of anemia: patients with refractory anemia RA with ringed 
sideroblasts, and RA with excess blasts (RAEB). Concomitant G-CSF or GM-CSF was used in two 
RCTs. Further delineation of major and minor Hb response was available in only two studies and 
transfusion outcomes also in two studies. Most authors reported dose reduction rules in the event 
of exceeding the target Hb or in the event of toxicity. Furthermore, all studies reported adverse 
events (AEs). Concurrent iron (as an oral supplement) was identified in only one study. The 
remaining studies were silent on the use of iron. In only one was the baseline serum 
erythropoietin level (<500 U/l) reported (Hb response OR:29.5, CI:1.9–531.2). 
 
Table 2. Patient’s characteristics 
Author Year Ethnicity 
 
Number of 
patient 
Mean age, 
years 
Men, 
% 
Platzbecker 2017 Europe 147 74 54.8 
Miller 2004 USA 109 73 NA 
Pierluigi 1998 Europe (Italy) 77 65 65 
Casadevall 2004 Europe (French) 60 72 50 
Thompson 2000 USA 66 62.5 70 
 
 
Table 3. Anemia treatment characteristics: ESP treatment groups 
Author ESP type Dosing frequency Dosing duration 
Platzbecker Darbepoetin a Once per 3 weeks 24 weeks 
Miller Epoetin a Every day 16 weeks 
Pierluigi Epoetin a Every day 8 weeks 
Casadevall Epoetin a 3 times a week 12 weeks 
Thompson Epoetin a 3 times a week 12 weeks 
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Efficacy of ESPs in MDS  
The main outcome of interest was the percentage of patients with Hb response. All studies 
used similar, but not exactly identical, criteria for Hb response. The main criteria were increase in 
Hb and need for transfusion. The most studies used the IWG criteria (or minor modifications).30  
Definitions of response criteria were defined as follows: full response: increase in Hb)>2g/dl (two 
consecutive controls in the same week) or no transfusion for at least 2 months; partial response: 
increase in Hb of 1–2g/dl (two consecutive controls in the same week) or 50% decrease in 
transfusion need for at least 2 months; no response: Hb change <1 g/dl or <50% reduction of 
transfusion requirements. Hb overall response is the sum of the major and minor responders. All 
five studies was this outcome available and analyzable. The Hb response rate was 24% ESPs group, 
and in control groups it was 5.6% (Table 4). The OR for Hb response was 5.59 (CI:2.74-11.42), 
significantly in favor of ESPs. An OR=5.59 means that there is 5.5 times greater chance of response 
when treated with ESPs than with placebo. There was no significant heterogeneity among the 
RCTs (P-value for Q=0.678). Heterogeneity was considered present when the P value of the 
Cochran Q test was P> 0.10, and so only the FE OR was considered. Note that RE OR coincides with 
the FE OR. The advantage for ESP was evident across all RCTs and reached statistical significance in 
three of five the studies (Fig. 1).  
 
Table 4. ESPs vs control: Hb response 
 Treatment Control OR Cl 
success total success total 
Platzbecker 11 75 0 35 11.86 0.68 – 207.96 
Miller 19 53 5 56 5.70 1.94 – 16.73 
Pierluigi 14 38 4 37 4.81 1.41 – 16.45 
Casadevall 10 30 0 30 29.50 1.63 – 532.26 
Thompson 4 45 1 21 1.95 0.20 - 18.62 
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Figure 1. Odds Ratio and 95%Cl 
 
In two studies the dosing frequency was three times per week, in two it was every day and 
in the remaining study was once per 3 weeks. The dosing duration was 12 weeks in two RCTs, 8 
weeks in one, 16 weeks in the other and 24 in the last one. Studies with a longer duration (16 and 
24 weeks) of ESPs use about the same Hb response rate (23.4%) (OR:6.24, Cl:2.,28-17.10) with 
studies with a shorter duration (8 and 12 weeks) of epoetin use (24.7%) (OR:5.01, Cl:1.82-13.77) 
(p=741).The duration of response and relapse rates were not efficacy outcomes for this analysis, 
and were rarely reported, because most studies did not provide long-term follow-up information. 
Casadevall et al reported that six of eight patients who continued epoetin past the initial 12-week 
study period relapsed, but they did not report time to relapse. Studies which the populations are 
from Europe (OR:6.91, Cl:2.41-19,78) had similar outcomes with studies from USA (OR:4.6, Cl:1.77-
12.34) 
 In one RCT there was analyzable data for major and minor response. The average major 
response rate in ESPs group was 13.2% (OR:5.3, Cl:0.59-47.2) and the minor response rate was  
23.7% (OR:2.56, Cl: 0.71-9.20) (Table 5). (Note: The major and minor response rates do not equal 
the total response rate here because of different studies contributing to each estimate.) In the 
four of five RCTs it was used epoetin a and in the remaining darbepoetin a.  In the epoetin group 
the total Hb response rate was 26.5% (OR:5.32, Cl:2.55-11.12). The OR is significant at P<0.05 and 
there is 5 times greater chance of response to ESP than to placebo.  While in the darbepoetin 
study response rate was 14.7% (11/75 evaluable) versus 0% (0/35 evaluable), (P=0.016) (OR: 5.85, 
CI: 0.72-47.2). Efficacy outcomes for the epoetin a studies and darbepoetin study are displayed in 
Institutional Repository - Library & Information Centre - University of Thessaly
07/06/2020 08:36:00 EEST - 137.108.70.13
11 
 
Table 6. Figure 2 summarizes the meta-analyzed results for Hb response outcomes for each type of 
treatment and type of response (minor and major). It appears that darbepoetin has inferior 
results, but the 95%CIs overlap with those of epoetin. Furthermore, the rate of transfused patients 
is 49.3% in ESPs group and 68.6% in control group. The OR=0.45 means that there is 55% less 
chance of transfusion when patients treated with ESPs than with supportive treatment. 
 
Table 5. Anemia response in MDS RTCs 
 n of studies 
with available 
data 
ESPs Control 
Odds ratio (95% Cl) (n) % (n) % 
Hb responders (%) 5 241 24 179 5.6 5.59 (2.74-11.42) 
Major 1 38 13.2 37 0.0 5.3 (0.59-47.2) 
Minor 1 38 23.7 37 10.8 2.56 (0.71-9.20) 
Patients 
transfused (%) 
2 142 49.3 70 68.6 0.45 (0.24- 0.81) 
 
Table 6. Epo vs Darb - anemia response  
Type of ESPs 
n of studies 
with available 
data 
ESPs Control 
Odds ratio (95% Cl) (n) % (n) % 
Epoetin a 4 166 26.5 144 7 5.32 (2.55-11.12) 
Darbepoetin 1 75 14.7 35 0.0 5.85 (0.72-47.2) 
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Figure 2. Odds Ratio and 95% Cl for time of treatment and type of response 
 
No concomitant chemotherapy, immunotherapy, hematopoietic stem cell transplant, other 
epigenetic therapy, or investigational treatments were included in the studies. Three used 
concurrent G-CSF or GM-CSF (Hb response OR:5.3, 95%CI:2.1-13.44), and one used concurrent oral 
iron (Hb response OR:4.6, 95% CI:1.4–15.2). The use of concomitant G-CSF showed little difference 
in efficacy outcomes (25% Hb response) compared with overall results (24% Hb response) 
(P=0.869) and with the studies which didn’t use concurrent treatment (OR:5.54, Cl:1.79-17.14) 
(P=0.617) (Table 7). In only one was the baseline serum erythropoietin level <500 U/l) reported 
(Hb response OR:29.5, 95% CI:1.9–531.2).   
 
Table 7. ESPs vs control efficiency with concurrent treatment 
Concurrent 
treatment 
n of studies 
with available 
data 
ESPs Control Odds ratio (95% Cl) 
(n) % (n) % 
G-CSF or GM-CSF 3 128 25 107 5.6 5.3 (2.1-13.44) 
None 2 113 22 72 4.6 5.54 (1.79-17.14) 
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Although, there was not heterogeneity in the analysis a meta-regression was conducted in 
order some baseline covariates upon the main efficacy outcome. The covariate age does not 
affects the response, P-value for b = 0.182 (P>0.10, not significant). Moreover, meta-regression 
analysis for the covariates: number of patients (P-value 0.842), ESPs type (P-value 0.657), gender 
(P-value 0.778) and duration (P-value 0.842) was not significant. Also, a sensitivity analysis for 
publication bias was conducted.  The Egger’s test was used the regression analysis. The P-value for 
testing whether the intercept a is 0 is P=0.528, i.e. the intercept a is not significant since P≥0.05. 
Therefore, there is no significant publication bias in the meta-analysis. Moreover, in the funnel 
plot there isn’t asymmetry that indicates the absence of publication bias (Fig 3). 
 
Fingure 3. Funnel plot for publication bias 
 
 
Safety of ESPs in MDS 
In none RTCs were reported statistical significant adverse events. But only in two RCTs the 
data were reported analytically (Platzbecker and Thomson). In order to Platzbecker et al the most 
frequently adverse events were patient-reported fatigue (darbepoetin alfa: 17.3%, placebo: 8.3%), 
asthenia (darbepoetin alfa: 12.2%, placebo: 10.4%) and exertional dyspnea (darbepoetin alfa: 
6.1%, placebo: 10.4%).  In order to Thomson et al the most frequently adverse events were skin 
reaction at rejection site (epoetin a: 33%, placebo: 57%), hepatomegaly (epoetin a: 8%, placebo: 
16%), splenomegaly(epoetin a: 8%, placebo: 16%), erythema (epoetin a: 6%, placebo: 19%), 
myalgia (epoetin a: 6.7%, placebo: 14.3%), thrombocytopenia (epoetin a: 11.1%, placebo: 0%), 
chills(epoetin a: 2%, placebo: 4%), headache (epoetin a: 2%, placebo: 4%), asthenia/fatigue 
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(epoetin a: 4%, placebo: 0%), pain in extremities (epoetin a: 2%, placebo: 0%), pyrexia (epoetin a: 
2%, placebo: 0%), allergic (epoetin a: 2%, placebo: 0%), stroke (epoetin a: 2%, placebo: 0%) and 
pericarditis (epoetin a: 2%, placebo: 0%). In Casadevall et al study, there were no adverse effects 
attributable to rHuEPO or rHuG-CSF and none of the deaths were linked to the treatment 
evaluated in the study. Although, one patient from ESPs group progressed to AML after 10 weeks 
of treatment, and another from control did so 20 weeks after inclusion. Moreover, in Pierluigi et al 
study adverse events occurred in 31.8% of the rHuEpo-treated versus 42.9% of the placebo-
treated patients (P=0.29, not statistical significant), but discontinuation of treatment before the 
eighth week was necessary only in seven cases (disease progression, one/each group; inefficacy of 
treatment, one/each group; stroke, one (epoetin a); skin rash, one; and personal reason one (both 
in the placebo group). The last study (Miller et al), the treatment was not associated with an 
increase rate of transformation to acute leukemia. Toxicities were comparable in all the treatment 
groups. 
 
Safety of ESPs in MDS 
Table 8. Adverse events of ESPs in MDS 
Category 
ESPs control Odds ratio (95% Cl) 
n total n AEs % n total n AEs % 
Total AEs 166 14 11.9 125 20 16 0.53 (0.24-1.19) 
Serious AEs 143 20 14 69 12 17.4 0.76 (0.35-1.68) 
Fatal AEs 143 4 2.8 69 3 14.3 0.60 (0.11-3.24) 
Thrombocytopenia 45 5 11.1 21 0 0 5.13 (0.08-44.21) 
Asthenia/fatigue 143 27 18.9 69 9 13 1.51 (0.66-3.45) 
Progression to AML 128 3 2.3 78 2 2.6 0.99 (0.16-6.21) 
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Figure 4. Odds ratio and 95%Cl for AEs 
 
Table 8 shows the frequencies of total and selected AEs, as well as the OR for these AEs. In 
these studies, event rates for all AEs captured were relative low. There wasn’t significant 
difference in the AEs rates (OR:0.53, Cl:0.24-1.19). None of the ORs in the selected AEs reached 
statistical significance. Odds ratio reported only for same study groups reporting event. The rates 
of serious and fatal AEs were higher in placebo group (not significant, OR:0.76, Cl:0.35-1.68 and 
OR:0.60, Cl:0.11-3.24). The rates of not serious AEs as asthenia and fatigue (ESPs:18.9%, 
control:13%) was lightly different in two groups (OR:1.51, Cl:0.66-3.45). Moreover, the rate of 
thrombocytopenia was not statistically different among the two groups (OR:5.13, Cl: 0.08-44.21) 
(Fig. 4). 
We note that progression to AML was captured only for the formal study period. 2% of 
ESPs patients and 2.1% of control patients progressed to AML. The OR is not significant (OR:0.99, 
Cl: 0.16-6.21), presumably because of the low numbers of patients and events. 
 
Discussion 
The present meta-analysis in the treatment of anemia of MDS, using a comprehensive list 
of epoetin alfa and darbepoetin RCTs, demonstrated higher erythroid response rates. Significant 
efficacy of ESPS versus standard care or placebo controls in terms of Hb response (OR: 5.59, 
95%CI: 2.74-11.42), the primary efficacy outcome in most of the studies reviewed.  
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The overall erythroid response rate (24%) found is higher to the modest efficacy of epoetin 
alfa observed in the first meta-analysis by Hellstrom-Lindberg et al. in 1995.  Comparatively little 
was known about MDS biology at the time of that publication. However, recently, greater 
refinement occurred in the treatment of these disorders. Noteworthy was the development of 
standardized response criteria, the IWG criteria, which permitted the comparison of efficacy of 
different agents in these rather diverse set of disorders. Another two meta-analyses about ESPs 
response in MDS patients were published 2007 and 2008. In the meta-analysis by Moyo et al was 
reported that response to ESPs was IWGc studies 57.6% and 31.6% non-IWGc studies (p<0.001) 
which is greater than present  meta-analysis. But, in this meta-analysis were included also non-
RCTs and maybe that is why the result differ. Moreover, Moyo et al study reported significantly 
higher erythroid response rates predominantly in the more recent studies that primarily utilized 
IWGc to define response which was not possible in the present study because not all RCTs 
followed the IWGc.  In the Ross et al study the rate of responses was 32.1% in epoetin single-arm 
studies and 27.3% RCTs in which are similar to the results of present study.22 
It has to be mentioned that there was only one darbepoetin RCTs and it makes difficult the 
analysis of epoetin versus darbepoetin response. In present meta-analysis the rates response in 
epoetin were higher than the rate of dabepoetin study. In contrast, in two meta-analyses, 
reported in 2006 and 2007, the response rates of drabepoetin are higher. In Mundle et al 
systematic review, with the use of standardized patient selection and response evaluation 
methods, epoetin alfa and darbepoetin alfa yielded comparable erythroid response rates in MDS 
patients. The epoetin groups achieved an Hb response rate of 57.6%, versus 59.4% for 
darbepoetin, but the difference was not statistical important (p=0.828).31 And in the Ross et al 
review the major Hb response rate averaged 38.8% in darbepoetin studies, also higher than in the 
epoetin single-arm studies (24.5%) and EvC studies (11.4%).22 This difference in findings is likely 
explained by different study eligibility criteria for each review, and until those details become 
available, interpretation remains difficult. Also, the total number of epoetin alfa and darbepoetin 
alfa studies in MDS is relatively small and data regarding reported durations of follow-up are 
limited, suggesting that these results be considered as hypothesis generating. Further head-to-
head randomized trials are necessary to compare the validity of the present results regarding 
efficacy of epoetin alfa and darbepoetin alfa in MDS. 
The evidence to date further suggests that a lower baseline erythropoietin level may be 
associated with a higher Hb response rate to ESPs. According to the aforementioned model, 
endogenous serum erythropoietin levels ≤500 mU/mL and transfusion requirement of <2 packed 
red blood cell units per month are predictive of improved response to ESA.32 This is plausible 
because refractory anemia in the face of a high endogenous erythropoietin level may indicate 
relative non responsiveness of bone marrow. Conversely, anemia associated with a low serum 
erythropoietin level may respond more readily to exogenous ESPs. These observations are further 
supported by the findings of other ESP studies.32,33,34 where in a lower serum erythropoietin level 
was associated with a greater Hb response rate to ESPs. These post hoc observations should be 
studied prospectively to determine if serum erythropoietin level could serve as a reliable guide to 
selection of MDS patients for ESP treatment. In present analysis, baseline erythropoietin level data 
were extractable only in one RCTs, so it could be analyzed. Mundle‘s et al meta-analysis supports 
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that lower mean baseline serum erythropoietin level associated with higher response rate in the 
epoetin alfa IWGc studies (p=0.007), because the percentage of transfusion-dependent patients 
was significantly higher in non IWGc studies where response rates were lower as well. 
The results of this meta-analysis also suggest that ESP treatment for a longer duration and 
the use of concurrent iron may not associated with a higher frequency of Hb response (little 
difference). These findings are in contrast with the previous review. So, further studies should be 
conducted in order to elucidate if these factor enhance efficiency of ESPs in MDS. As do extended 
dose regimens that may enhance convenience, adherence, and efficacy of long-term regimens.  
As for the other efficacy outcomes of interest as percentage of patients transfused, the 
rate of ESPs group (49.3%) was significant lower than control group (68.6%). It is suggested that 
QoL improves in ESP-treated patients, and this improvement is of a magnitude that is clinically 
meaningful. Furthermore, transfusion-dependent patients are likely to have lower Hb values than 
non-transfusion-dependent patients, and anemia has been shown to be a significant risk factor for 
both survival and cardiovascular diseases.35 It is not unreasonable to speculate that ESAs, by 
reducing transfusion dependency and correcting anemia, may positively impact survival. But the 
available evidence is less compelling than for Hb response outcomes, because only 2 studies had 
extractable data.  
As it’s known from literature, granulocyte-colony-stimulating factor (G-CSF) and granulocyte 
macrophage-colony-stimulating factor (GM-CSF) increase neutrophil counts, do not increase the 
risk for leukemia, and have no effect on survival.36 In present study, the results are similar. The 
concurrent treatment with G-CSF or GM-CSF isn’t associated with higher Hb response compare to 
studies which did use concurrent treatment. So, the use of ESPs as monotherapy or in combination 
with G-CSF, is associated with improved survival. This is plausible considering the possible impact 
of transfusion and related iron overload on survival in MDS patients 
As for the safety of ESPs, AEs rates were generally low in all studies and in one study none 
AE reported. Percentage of total AEs, serious and fatal AEs were even higher in the control group. 
Moreover, selected AEs, thrombocytopenia, asthenia and fatigue were more in ESPs group but the 
difference has not statistical important. Although, concerns have been raised previously about the 
danger of progression to AML due to these agents, ESPs has not been associated with higher rates 
in present study. In none study, ant death was attributed in ESPs. The causes of death, with the 
exception of thrombocytopenia-related bleeding, are similar to those found in other disease states 
such as the thalassemias where chronic transfusion results in iron overload.37 Whether there are 
differences in safety among ESPs, and whether ESPs will be proven to be safe with the long-term 
use that may be needed in MDS, remain to be seen. Only comparative, long-term follow-up trials 
will resolve these questions. 
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Conclusion 
Ιn this meta-analysis, the RCTs included comprise the best available evidence on the 
efficacy and safety of ESPs in the treatment of anemia associated with MDS. Patients with MDS 
treated with ESPs showed significantly higher erythroid response rates over time. Although the 
evidence for darbepoetin is sparse, thus far it appears that darbepoetin is as effective as epoetin. 
Random controlled trials of darbepoetin versus standard care or placebo controls are needed to 
establish not only the efficacy and safety, but also the costs and health care use associated with 
these treatment alternatives. Head-to-head trials of epoetin versus darbepoetin are also needed 
to compare Hb response in comparable patients using comparable response criteria, as well as 
QoL and other efficacy measures of potential interest, such as safety, long-term benefit, long-term 
survival, relapse rates, and AML progression. 
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